TELIX PHARMACEUTICALS LIMITED
ASX:TLXPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 90.7% of what they think they own, once every option and right converts.
1 cash raise in 24 months; options/rights overhang 10% of shares
TELIX PHARMACEUTICALS LIMITED's ordinary share count grew 1.7% between October 2024 and October 2026, its latest share-count filing, to 340M shares. The company raised capital once in that period for total disclosed proceeds of A$847.1M, through convertible notes in April 2026. Options and rights could convert into 35M new shares, equal to 10.2% of the current share count, none of which are in the money; the nearest expiry is June 2027. The company's latest cash report is a half-year/annual report showing non-negative net cash flow, so no funding-runway figure applies. No proposed securities issues are pending.
Quick answers · 3
When did TLX last raise capital?
The last capital raise in Telix Pharmaceuticals's filings is Convertible Notes of $847.1M announced 15 Apr 2026, one of 1 cash raises in 24 months.
When do TLX's options expire?
Unexercised options and rights equal 10.2% of Telix Pharmaceuticals's shares on issue; the nearest expiry is June 2027.
How much has TLX's share count grown?
Telix Pharmaceuticals has 340.3M shares on issue as at 28 Oct 2026, up 1.7% over 24 months according to its Appendix 2A filings.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 28 Oct 2026 | 2A · quoted issue | TLX : ORDINARY FULLY PAID | 340.3M | Appendix 2A |
| 5 Oct 2026 | 2A · quoted issue | TLX : ORDINARY FULLY PAID | 340.3M | Appendix 2A |
| 5 Oct 2026 | 3G · unquoted | ORDINARY FULLY PAID | 339.9M | Appendix 3G |
| 5 Oct 2026 | 3H · cancellation | TLX : ORDINARY FULLY PAID | 339.9M | Appendix 3H |
| 25 Sept 2026 | 2A · quoted issue | TLX : ORDINARY FULLY PAID | 339.9M | Appendix 2A |
Securities on issue over time
Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.
Capital raises
1 cash raise in the last 24 months · 1 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
No option supply on record carries an exercise price to pay, so no share price switches any of it on. 15k of it states a NIL exercise price — nothing is paid to convert that, so it converts at any price. The other 34.8M converts on something else — a hurdle that may never be met, or terms the filing does not price.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| TLXAQ | Rights | Condition-triggered | Nil | 13 June 2027 | 15k | Filing Meeting |
| TLXAU | Rights | Condition-triggered | — | — | 7k | Filing Meeting |
| TLXAY | Rights | Condition-triggered | — | — | 66k | Filing Meeting |
| TLXAX | Rights | Condition-triggered | — | — | 88k | Filing Meeting |
| TLXAZ | Rights | Condition-triggered | — | — | 431k | Filing Meeting |
| TLXAS | Performance shares | Condition-triggered | — | — | 440k | Filing Meeting |
| TLXAP | Rights | Condition-triggered | — | — | 1.1M | Filing Meeting |
| TLXAW | Performance shares | Condition-triggered | — | — | 8.3M | Filing Meeting |
| TLXAR | Performance rights | Condition-triggered | — | — | 10.0M | Filing Meeting |
| TLXAO | Rights | Condition-triggered | — | — | 14.4M | Filing Meeting |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.
A condition-triggered class has no exercise price and usually no expiry: what it vests on is set by a shareholder resolution, not by the register. Where the company lodged a notice of meeting before the class first appears here, it is linked as “Meeting” — that is where terms of this kind are put to shareholders. It is not confirmation that the document sets this class’s conditions, and no link appears where there is no such filing.
- TLXAVCondition-triggered2k securities → 012 Mar 2026 Appendix 2A
- TLXATconvertible notes6k28 Oct 2026 Appendix 2A
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 26 Oct 2026 | Dr Christian Behrenbruch | Buy on-market | 39k | — | — | — | 3Y notice |
| 23 Oct 2026 | David Gill | Other on-market | 3k | — | — | — | 3Y notice |
| 22 Oct 2026 | William Jellison | Buy on-market | 25k | — | — | — | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.